undamentalytics Newsletter

Coliseum Capital Partners, L.P.: insider trades

Director, 10% owner at 6 companies we cover. 11 open-market purchases and 3 sales not made under a pre-set plan, reported from December 11, 2015 to June 10, 2026.

Would copying Coliseum Capital Partners, L.P.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 9 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on May 23, 2018 into $714 by November 2, 2026, −26.9% a year. The copy held shares only 53% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $15,489, +5.3% a year (the S&P 500 held throughout made $31,475, +14.6% a year). Beta against the index was 0.73. Twelve months after each report, the average purchase was −28.5% against the S&P 500 (median −31.4%), and 22% beat it. Measured from the trade date, the insider’s own timing, the average was −26.3%. After their sales, the shares moved +11.1% against the index over 12 months on average (a negative figure means selling was the right call); 0% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k$30.0k 201820192020202120222023202420252026 $31.5k$15.5k$714
Copying Coliseum Capital Partners, L.P.S&P 500, same days investedS&P 500, held throughout $10,000 copying Coliseum Capital Partners, L.P.’s open-market purchases from May 23, 2018, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−26.9%
S&P 500, same days invested
+5.3% (held throughout +14.6%)
Time in shares
53%
Sharpe ratio (S&P 500)
−0.34 (0.66)
Biggest drop (S&P 500)
−95% (−34%)
Market sensitivity (beta)
0.73
Purchases copied
9

Trade by trade

Coliseum Capital Partners, L.P.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 9 −15.3% −9.9% 22% 4 −2.25 0.11 No reliable evidence
Purchases, 6 months after the report 9 −2.8% −11.0% 22% 4 −0.51 0.65 No reliable evidence
Purchases, 12 months after the report 9 −28.5% −31.4% 22% 4 −4.61 0.019 Some evidence: behind
Purchases, 12 months after the trade 9 −26.3% −28.7% 22% 5 −3.27 0.031 Some evidence: behind
Sales, 3 months after the report 3 −17.9% −3.9% 67% 2 — — Not enough years
Sales, 12 months after the report 2 +11.1% +11.1% 0% 1 — — Not enough years
Sales, 12 months after the trade 2 +15.6% +15.6% 0% 1 — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Universal Technical Institute Inc UTI —21December 11, 2015June 10, 2026
Purple Innovation, Inc. PRPL —30May 22, 2018March 31, 2022
Mastercraft Boat Holdings, Inc. MCFT —30May 22, 2024June 17, 2024
Blue Bird Corp BLBD —02February 16, 2017September 26, 2017
Sonos Inc SONO —20April 7, 2025June 16, 2025
Accendra Health Inc ACH —10August 14, 2025August 14, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
June 10, 2026June 8, 2026 UTI Sale $124,200,000 −54.1%not yetnot yet
August 14, 2025August 12, 2025 ACH Purchase $8,099,544 −53.1%−100.7%−102.3%
June 16, 2025June 12, 2025 SONO Purchase $6,580,893 +39.2%+19.1%+20.1%
April 7, 2025April 3, 2025 SONO Purchase $1,873,230 +9.6%+20.7%+26.3%
June 17, 2024June 13, 2024 MCFT Purchase $3,803,255 −9.9%−16.8%−22.6%
May 28, 2024May 23, 2024 MCFT Purchase $1,702,315 −8.0%−31.7%−31.4%
May 22, 2024May 20, 2024 MCFT Purchase $7,257,188 −7.9%−31.4%−28.7%
March 31, 2022March 30, 2022 PRPL Purchase $4,205,500 −27.2%−49.9%−49.8%
January 4, 2022December 31, 2021 PRPL Purchase $4,107,500 −49.5%−44.2%−45.8%
May 22, 2018May 18, 2018 PRPL Purchase $2,033,107 −30.9%−21.1%−2.1%
September 26, 2017September 23, 2017 BLBD Sale $13,848,856 −3.9%+5.3%+15.3%
February 16, 2017February 14, 2017 BLBD Sale $4,137,953 +4.1%+16.8%+15.9%
December 31, 2015December 29, 2015 UTI Purchase $1,544,884 not yetnot yetnot yet
December 11, 2015December 9, 2015 UTI Purchase $1,231,502 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Coliseum Capital Partners, L.P. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.